

REMARKS

With this preliminary amendment, the Applicant modifies the specification to include cross reference of related applications. Claims 1-25 are cancelled herewith and new claims 26-48 are added. No new matter is added.


Support for “a method for stimulating an immune response in a human” such as a “systemic or humoral immune response” is found at least on page 8, lines 24-28 and 30-33 and page 9 lines 22-25. Support for “phosphorothioate oligonucleotide analog” and “immunopotentiator” and “modified analogs” etc is found throughout the summary and detailed description, for instance on page 8 line 10 – page 9 line 10 and page 10 line 36 – page 11 line 35. Support for administering via “inhalation, ophthalmic, intranasal, parenteral, oral or intradermal” is found on page 13 lines 16-24. Support for the oligonucleotide is not “antisense” is found on page 8 lines 10-15 and page 10 line 16 – page 11 line 1. Support for treatment of “cancer, infection, or surgery” and “administration of a therapeutic modality” is found page 8 lines 15-19, page 9, lines 1-2 and 32-33 and page 10 lines 3-9 and 16-21. Support for “the phosphorothioate oligonucleotide analog is an immunopotentiator of an antibody response” is found on page 8 lines 26-28. Support for “formulations such as liposomes and cationic lipids” is found on page 13 lines 26 – 31 and page 15 lines 8-10.

CONCLUSION

If the Examiner has any questions he/she is requested to call the Applicant's attorney at the telephone number listed below. If there is a fee occasioned by this response, including an extension fee, that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Respectfully submitted,

Hutcherson and Glover, Applicants



By: Helen C. Lockhart, Reg. No. 39,248
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Telephone: (617) 720-3500
Representative for Applicants

Attorney's Docket No.: C01037.70049.US

Date: August 18, 2003

xNDDx